- Aerie to acquire Avizorex (AVX) in an all-cash transaction. Avizorex to receive $10M up front, development & regulatory milestones with royalties in sales of the approved product in its development pipeline. The acquisition is expected to be close in H2’19
- Aerie to get rights to acquire Avizorex’s lead candidate AVX-012 along with other compounds targeting TRPM8. The acquisition will foster Aerie’s dry eye product portfolio with the addition of Avizorex’s AVX-012.
- AVX-012 is a potent and selective agonist of the TRPM8 ion channel, acts by restoring the tear film stability and reduce discomfort in patients with dry eye, supported by P-IIa study to treat signs and symptoms of dry eye with its anticipated onset of P-IIb study in H2’2020
Click here to read full press release/ article | Ref: Businesswire | Image: AVX Pharma